Future research may identify biomarkers that predict the ideal maintenance dose and escalation speed for individual patients, allowing personalized peptide protocols that maximize efficacy while minimizing side effects
May 12, 2026 Articles, Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Obesity, Obesity, Practice Management, Type 2 Diabetes, Type 2 Diabetes 1,345 views A patient starts semaglutide through a telehealth platform, receives nutrition advice from a wellness clinic, and later visits a primary care physician for worsening gastrointestinal symptoms
We also have various other related assays, including ELISA kits for other species and CLIA kits
Our prior studies show that adherence for GLP-1 drugs in the real-world is low
In many cases, the answer lies in a mix of side effects, cost, and patient expectations